Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: A randomized clinical trial

American Journal of Kidney Diseases

Volumn 59, Issue 2, 2012, Pages 177-185

  Yilmaz, Mahmut Ilker ^a   Sonmez, Alper ^a   Saglam, Mutlu ^a   Yaman, Halil ^a   Kilic, Selim ^a   Eyileten, Tayfun ^a   Caglar, Kayser ^a   Oguz, Yusuf ^a   Vural, Abdulgaffar ^a   Yenicesu, Mujdat ^a   Mallamaci, Francesca ^b   Zoccali, Carmine ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

chronic kidney disease; endothelial dysfunction; Fibroblast growth factor 23; inflammation; sevelamer

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; CALCIUM ACETATE; FETUIN A; FIBROBLAST GROWTH FACTOR 23; HEMOGLOBIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOS EX; PHOSPHATE; SERUM ALBUMIN; SEVELAMER; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR FUNCTION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG DOSE REDUCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MUSCLE CRAMP; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VASODILATATION;

ACETATES; ADULT; CALCIUM COMPOUNDS; CHELATING AGENTS; CHRONIC DISEASE; COMORBIDITY; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTORS; FOREARM; HUMANS; HYPERPHOSPHATEMIA; KIDNEY DISEASES; MIDDLE AGED; PHOSPHATES; POLYAMINES; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VASODILATION;

EID: 84855827125     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2011.11.007     Document Type: Article

References (30)

1. Q.L. Zhang, D. Rothenbacher Prevalence of chronic kidney disease in population-based studies: systematic review BMC Public Health 8 2008 117
2. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 13 2004 1296 1305
3. C. Zoccali Traditional and emerging cardiovascular and renal risk factors: an epidemiologic perspective Kidney Int 70 1 2006 26 33 (Pubitemid 44000117)
4. E. Shuto, Y. Taketani, R. Tanaka et al. Dietary phosphorus acutely impairs endothelial function J Am Soc Nephrol 20 7 2009 1504 1512
5. M. Wolf Fibroblast growth factor 23 and the future of phosphorus management Curr Opin Nephrol Hypertens 18 2009 463 468
6. B.D. Parker, L.J. Schurgers, V.M. Brandenburg et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study Ann Intern Med 152 10 2010 640 648
7. M.A. Mirza, A. Larsson, H. Melhus, L. Lind, T.E. Larsson Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population Atherosclerosis 207 2009 546 551
8. O.M. Gutierrez, J.L. Januzzi, T. Isakova et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease Circulation 119 2009 2545 2552
9. O.M. Gutierrez, M. Mannstadt, T. Isakova et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis N Engl J Med 359 2008 584 592
10. R. Nagai, Y. Saito, Y. Ohyama et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases Cell Mol Life Sci 57 2000 738 746 (Pubitemid 30392032)
11. M.A. Mirza, A. Larsson, L. Lind, T.E. Larsson Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community Atherosclerosis 205 2009 385 390
12. M.I. Yilmaz, A. Sonmez, M. Saglam et al. FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease Kidney Int 78 7 2010 679 685
13. D.M. Antoniucci, T. Yamashita, A.A. Portale Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men J Clin Endocrinol Metab 91 2006 3144 3149 (Pubitemid 44271770)
14. R.B. Oliveira, A.L. Cancela, F.G. Graciolli et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5 2 2009 286 291
15. F. Koiwa, J.J. Kazama, A. Tokumoto ROD21 Clinical Research Group Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients Ther Apher Dial 9 2005 336 339 (Pubitemid 41800805)
16. K. Caglar, M.I. Yilmaz, M. Saglam et al. Short-term treatment with sevelamer increases serum fetuin-A concentration and improves endothelial dysfunction in chronic kidney disease stage 4 patients Clin J Am Soc Nephrol 3 2008 61 68
17. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470 (Pubitemid 29135798)
18. D.S. Celermajer, K.E. Sorensen, V.M. Gooch et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis Lancet 340 1992 1111 1115
19. T. Nakamura, Y. Saito, Y. Ohyama et al. Production of nitric oxide, but not prostacyclin, is reduced in klotho mice Jpn J Pharmacol 89 2002 149 156 (Pubitemid 34752300)
20. L. Lind Impact of ageing on the measurement of endothelium-dependent vasodilatation Pharmacol Rep 58 Suppl 2006 41 46
21. G.F. Mitchell, H. Parise, J.A. Vita et al. Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study Hypertension 44 2004 134 139 (Pubitemid 39014228)
22. M.A. Mirza, T. Hansen, L. Johansson et al. Relationship between circulating FGF23 and total body atherosclerosis in the community Nephrol Dial Transplant 24 2009 3125 3131
23. A.L. Zisman, M. Wolf Recent advances in the rapidly evolving field of fibroblast growth factor 23 in chronic kidney disease Curr Opin Nephrol Hypertens 19 4 2010 335 342
24. D. Fliser, B. Kollerits, U. Neyer et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study J Am Soc Nephrol 18 9 2007 2600 2608
25. N.M. Hamburg, M.J. Keyes, M.G. Larson et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study Circulation 117 2008 2467 2474 (Pubitemid 351670453)
26. S. Fichtlscherer, S. Breuer, A.M. Zeiher Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes: further evidence for the existence of the "vulnerable" patient Circulation 110 2004 1926 1932 (Pubitemid 39331903)
27. F. Perticone, R. Ceravolo, A. Pujia et al. Prognostic significance of endothelial dysfunction in hypertensive patients Circulation 104 2001 191 196 (Pubitemid 32655837)
28. G.M. London, B. Pannier, M. Agharazii, A.P. Guerin, F.H. Verbeke, S.J. Marchais Forearm reactive hyperemia and mortality in end-stage renal disease Kidney Int 65 2004 700 704 (Pubitemid 38130668)
29. T.F. Luscher, G. Noll Endothelial function as an end-point in interventional trials: concepts, methods and current data J Hypertens Suppl 14 1996 S111 S119
30. T. Isakova, H. Xie, W. Yang Chronic Renal Insufficiency Cohort (CRIC) Study Group Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease JAMA 305 23 2011 2432 2439